Generate Biomedicines raises $370M Series B with a focus on protein-based drugs
![](https://www.signifyresearch.net/wp-content/uploads/2021/12/Picture2-624x406-1.png)
![Imogen Fitt headshot](https://www.signifyresearch.net/wp-content/uploads/2023/12/Signify-Imogen_F-Profile-@2-150x150.png)
Imogen Fitt
Published: December 6, 2021 In The News
18th November 2021 – Featured on Techcrunch.com – The drug development space is continuing to attract more and more investment. On Thursday, another major player, Generate Biomedicines, announced a $370 million Series B round.
Generate Biomedicines is touting a platform-based approach to drug development, but with its own spin: a focus on proteins.
You may also like